Cargando…

Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy

SIMPLE SUMMARY: The development of a simple tool that uses pretreatment clinical factors to predict the 6-month mortality rate of patients with advanced biliary tract cancer is critical in order to assist physicians in evaluating treatment options and outcomes. We established a nomogram including fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chiao-En, Huang, Wen-Kuan, Chou, Wen-Chi, Hsieh, Chia-Hsun, Chang, John Wen-Cheng, Lin, Cheng-Yu, Yeh, Chun-Nan, Chen, Jen-Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268608/ https://www.ncbi.nlm.nih.gov/pubmed/34201707 http://dx.doi.org/10.3390/cancers13133139

Ejemplares similares

Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience
por: Wu, Chiao-En, et al.
Publicado: (2020)

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
por: Wu, Chiao-En, et al.
Publicado: (2020)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer
por: Zhao, Qing, et al.
Publicado: (2015)

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters
por: Chang, Yau-Ren, et al.
Publicado: (2021)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

A nomogram to predict overall survival for biliary tract cancer
por: Song, Wei, et al.
Publicado: (2018)

Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation
por: Pan, Yi-Ru, et al.
Publicado: (2023)

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
por: André, T, et al.
Publicado: (2008)

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer
por: Nakashima, Shinsuke, et al.
Publicado: (2015)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Factors associated with distinct prognostic‐awareness‐transition patterns over cancer patients’ last 6 months of life
por: Chen, Chen Hsiu, et al.
Publicado: (2021)

mTOR Inhibitors in Advanced Biliary Tract Cancers
por: Wu, Chao-En, et al.
Publicado: (2019)

Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone
por: Murata, Akihiro, et al.
Publicado: (2013)

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
por: Tsukiyama, Ikuto, et al.
Publicado: (2016)

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction
por: Shibata, Takashi, et al.
Publicado: (2016)

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract
por: Hsu, C, et al.
Publicado: (2004)

Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio–EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy
por: Huang, Zhang-Zan, et al.
Publicado: (2021)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
por: Zhou, Jun, et al.
Publicado: (2023)

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
por: Chiang, Nai-Jung, et al.
Publicado: (2022)

A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis
por: Tian, Siyuan, et al.
Publicado: (2020)

A Nomogram Predicting the Prognosis of Children With Biliary Atresia After Hepatoportoenterostomy
por: Liu, Jin-qiao, et al.
Publicado: (2021)

Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials
por: Chiang, Nai-Jung, et al.
Publicado: (2021)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
por: Zeng, Tian-mei, et al.
Publicado: (2023)

Gemcitabine and S-1 Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer: A Retrospective Study
por: Mita, Kazuhito, et al.
Publicado: (2010)

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines
por: Sakamoto, Yasunari, et al.
Publicado: (2019)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges
por: Huang, Wen-Kuan, et al.
Publicado: (2022)

Risk of Mortality and Readmission among Patients with Pelvic Fracture and Urinary Tract Infection: A Population-Based Cohort Study
por: Chen, Ying-Cheng, et al.
Publicado: (2021)

Hematological Indices of Distant Metastases and Prognostic Nomogram in Gastro-Pancreatic and Biliary Tract Cancers
por: Mansour, Razan, et al.
Publicado: (2020)

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
por: Okusaka, T, et al.
Publicado: (2010)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
por: Lee, Jieun, et al.
Publicado: (2015)

Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101)
por: Fujiwara, Yutaka, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u0a1cih1e6vout4tv8kpb5lh4l